Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.41 |
| ▸ | PPARA | Q07869 | 13/20 | 0.41 |
| ▸ | PPARG | P37231 | 10/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21382493 | 1.00 | PPARD (0.41) | PPARDPPARAPPARGHSD17B3NPC1 | |
| SCHEMBL21454174 | 0.90 | PPARD (0.41) | PPARDPPARAPPARGHSD17B3ROCK2 | |
| SCHEMBL21382462 | 0.90 | PPARD (0.41) | PPARDPPARAPPARGHSD17B3ROCK2 | |
| Hydrochloric Acid SCHEMBL21382356 | 0.89 | PPARD (0.41) | PPARDPPARAPPARGHSD17B3ROCK2 | |
| SCHEMBL21454461 | 0.88 | ALDH1A1 (0.40) | PPARDPPARAPPARGSMN1; SMN2ROCK2 | |
| SCHEMBL21454274 | 0.87 | CYP1A2 (0.34) | PPARDPPARAPPARGHSD17B3ROCK2 | |
| SCHEMBL21453703 | 0.87 | MEN1 (0.39) | PPARDPPARAPPARGHSD17B3AOC3 | |
| SCHEMBL21384709 | 0.87 | CYP1A2 (0.34) | PPARDPPARAPPARGHSD17B3ROCK2 | |
| SCHEMBL21454168 | 0.87 | MEN1 (0.39) | PPARDPPARAPPARGHSD17B3AOC3 | |
| SCHEMBL29981302 | 0.87 | CYP1A2 (0.34) | PPARDPPARAPPARGHSD17B3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111886227-B | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2023-10-13 | — | — | CN | claimed |
| CN-111886227-A | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2020-11-03 | — | — | CN | claimed |
| US-10562865-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2020-02-18 | — | — | US | claimed |
| US-20190308944-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-10 | — | — | US | claimed |
| CN-111886227-B | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2023-10-13 | — | — | CN | disclosed |
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2022-11-08 | — | — | US | disclosed |
| US-20210147368-A1 | ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| US-20210147368-A1 | ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| EP-3768663-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2021-01-27 | — | — | EP | disclosed |
| US-10899719-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2021-01-26 | — | — | US | disclosed |
| CN-111886227-A | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2020-11-03 | — | — | CN | disclosed |
| US-20200223808-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-20200223808-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2020-07-16 | — | — | US | disclosed |
| US-10562865-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2020-02-18 | — | — | US | disclosed |
| US-10562865-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2020-02-18 | — | — | US | disclosed |
| US-20190308944-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-10 | — | — | US | disclosed |
| US-20190308944-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-10-10 | — | — | US | disclosed |
| WO-2019180644-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
| US-10562865-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
| US-20190308944-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CYP7A1, VAPB, SLC10A1 | PPARD 99/4885PPARA 57/4885PPARG 20/4885 |
| US-10899719-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
| US-20200223808-A1 | NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CYP7A1, VAPB, SLC10A1 | PPARD 99/4885PPARA 57/4885PPARG 20/4885 |
| US-20210147368-A1 | ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.